Verona Pharma plc
VRNA
Rang in aandelen
#2232
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Aandeelprijs
$106.91
Laatst gesynchroniseerd: 2025-10-07
Marktkapitalisatie
$9.09B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
GB
Handel Verona Pharma plc (VRNA)
Categorie
Healthcare
P/B-ratio voor Verona Pharma plc (VRNA)
P/B-ratio op October 2026 TTM: 41.96
Volgens de meest recente financiële rapporten en aandelenkoers van Verona Pharma plc is de huidige P/B-ratio (TTM) 41.96. Eind 2023 had het bedrijf een P/B-ratio van 6.02.
P/B-ratiohistoriek voor Verona Pharma plc van 2005 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 41.96 | 130.17% |
| 2024 | 18.23 | 202.67% |
| 2023 | 6.02 | -19.60% |
| 2022 | 7.49 | 178.89% |
| 2021 | 2.69 | 115.77% |
| 2020 | 1.24 | -3.18% |
| 2019 | 1.29 | 3.29% |
| 2018 | 1.24 | 34.11% |
| 2017 | 0.93 | -13.81% |
| 2016 | 1.08 | -61.46% |
| 2015 | 2.79 | 192.12% |
| 2014 | 0.96 | -53.11% |
| 2013 | 2.04 | 34.88% |
| 2012 | 1.51 | 42.73% |
| 2011 | 1.06 | -15.01% |
| 2010 | 1.25 | 40.84% |
| 2009 | 0.89 | -26.97% |
| 2008 | 1.21 | 33.07% |
| 2007 | 0.91 | 31.45% |
| 2006 | 0.69 | -80.59% |
| 2005 | 3.57 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -85.10% |
US
|
|
| 13.2547 | -68.41% |
US
|
|
| 4.208 | -89.97% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -85.27% |
NL
|
